Key Updates
Eli Lilly declined 2.82% to $1,015.21 since the February 10th report, breaking below the critical $1,050 support level and extending YTD losses to -5.53%. The stock has now declined 8.30% over the past five trading days despite positive fundamental developments. This price action follows the release of a Forbes analysis highlighting the company's 60% six-month rally and identifying key growth drivers including the oral GLP-1 drug Orforglipron expected by mid-to-late 2026, expanded manufacturing capacity achieving 1.8x incretin dose production in 2025, and improving operating margins. The disconnect between strong fundamentals and declining price suggests profit-taking after the post-earnings rally, with the stock trading at a premium P/E of 49.9x despite 45.4% revenue growth and 44.4% operating margins.
Current Trend
The stock has entered a corrective phase after reaching near-record levels following the February 4th earnings beat. YTD performance stands at -5.53%, with the recent decline establishing a clear downtrend from the post-earnings high of approximately $1,150. The $1,050 level, which served as support in the February 6th and 10th reports, has been decisively broken, with the current price at $1,015.21 representing the lowest level since the earnings announcement. The 5-day decline of -8.30% and 1-month decline of -6.09% indicate accelerating downward momentum, while the 6-month gain of 59.82% confirms the longer-term uptrend remains intact. Key resistance now sits at $1,050 (former support), with potential support at the psychological $1,000 level.
Investment Thesis
The core investment thesis centers on Eli Lilly's dominant position in the high-growth GLP-1 obesity and diabetes market, with Zepbound capturing nearly 70% of new U.S. GLP-1 prescriptions and Mounjaro securing 55% market share. The company delivered exceptional Q4 2025 results with 43% revenue growth to $19.3 billion and provided strong 2026 guidance of $80-83 billion revenue (25% growth) and $34.25 adjusted EPS (41% growth at midpoint), significantly exceeding analyst expectations. Manufacturing capacity expansion achieving 1.8x incretin dose production positions Lilly to meet surging demand, while the anticipated approval of oral GLP-1 drug Orforglipron in Q2 2026 and next-generation retatrutide (demonstrating 28.7% weight loss in Phase 3 trials) provide substantial pipeline catalysts. The thesis is reinforced by Lilly's competitive advantage versus Novo Nordisk, which has guided for declining 2026 revenue due to pricing pressures and market share losses.
Thesis Status
The investment thesis remains fundamentally intact and has strengthened based on recent operational performance, though valuation concerns have intensified. The Morningstar analysis raised its fair value estimate to $870 from $770 but cautioned that current share prices may exceed intrinsic value, while CNBC raised its price target to $1,250 based on GLP-1 market dominance. The company's Q4 results validated the growth trajectory with Mounjaro and Zepbound sales exceeding $11.7 billion (versus $10.4 billion estimates), and 2026 guidance implies continued market leadership. However, the Forbes report identifies emerging risks including potential GLP-1 price competition, Medicare rebates creating low-to-mid teens pricing pressure, capital expenditure execution challenges with $50 billion committed to U.S. manufacturing, and product liability concerns related to vision loss. The current price decline appears driven by valuation normalization rather than thesis deterioration.
Key Drivers
The primary near-term catalyst is the anticipated FDA approval of oral GLP-1 drug Orforglipron expected by mid-to-late 2026, which could significantly expand market access versus injectable alternatives. Manufacturing capacity expansion remains critical, with the company achieving 1.8x incretin dose production in 2025 and announcing a $3.5 billion Pennsylvania facility to produce next-generation retatrutide, expected operational in 2031. Medicare coverage for obesity medications with a $50 copay beginning July 1, 2026, represents a major demand driver, though it introduces pricing pressure through government access agreements. The company's deal with the Trump administration promising steep price cuts for Medicare, Medicaid, and cash payers in exchange for tariff exemptions creates a complex dynamic where volume growth must offset pricing headwinds. Competitive positioning versus Novo Nordisk has improved dramatically, with Lilly forecasting strong 2026 growth while its rival projects sales declines.
Technical Analysis
The stock has broken below the $1,050 support level that held during the February 6th and 10th corrections, establishing a new lower high pattern at approximately $1,150 post-earnings. The current price of $1,015.21 represents a 2.82% decline from the previous report and sits 11.7% below the post-earnings peak. The 5-day decline of -8.30% indicates accelerating bearish momentum, while the 1-month decline of -6.09% confirms the corrective phase. The psychological $1,000 level represents the next major support, with a break below potentially targeting the $950-970 range. Resistance has now formed at $1,050 (former support), followed by $1,100 and the $1,150 recent high. The 6-month gain of 59.82% provides substantial cushion for the current correction, suggesting the longer-term uptrend remains valid. Volume patterns during the decline will be critical to assess whether this represents profit-taking or a more significant sentiment shift.
Bull Case
- Exceptional Q4 2025 results with sustained market dominance: Revenue increased 43% to $19.3 billion (versus $17.9 billion estimate) with Zepbound generating $4.3 billion (up 123%) and Mounjaro producing $7.4 billion (up 110%), demonstrating Lilly's commanding position with Zepbound capturing 70% of new U.S. GLP-1 prescriptions and Mounjaro securing 55% market share. Source: CNBC
- Superior 2026 guidance significantly exceeding expectations: Management projects $80-83 billion revenue (25% growth versus consensus $77.62 billion) and $33.50-$35 adjusted EPS (41% growth at midpoint versus consensus $33.23), contrasting sharply with competitor Novo Nordisk's warning of unprecedented pricing pressures and steep sales decline. Source: Reuters
- Oral GLP-1 Orforglipron approval expected mid-to-late 2026: The anticipated FDA approval of oral Orforglipron represents a significant market expansion opportunity versus injectable alternatives, with manufacturing capacity achieving 1.8x incretin dose production in 2025 positioning the company to meet surging demand. Source: Forbes
- Next-generation pipeline with superior efficacy: Retatrutide demonstrated 28.7% average body weight loss at 68 weeks in Phase 3 trials, exceeding current obesity treatment Zepbound's efficacy, with a $3.5 billion Pennsylvania manufacturing facility announced to produce this next-generation therapy expected operational in 2031. Source: CNBC
- Improving operating margins driven by high-margin GLP-1 products: The company reported 44.4% operating margin with revenue growth of 45.4% over the last twelve months, with high-margin GLP-1 products like Zepbound and Mounjaro driving profitability expansion that substantially exceeds S&P 500 averages across gross, operating, and net margins. Source: Forbes
Bear Case
- Extreme valuation premium at 49.9x P/E multiple: The stock trades at approximately 5x the market's P/S ratio and nearly 3x its P/E ratio at 49.9x, with Morningstar analysts cautioning that current share prices may exceed intrinsic value despite raising their fair value estimate to $870, suggesting limited upside from current $1,015 levels. Source: Forbes
- Significant pricing pressure expected in 2026: The company expects low-to-mid teens pricing declines due to government access agreements, Medicare rebates, and discounted programs including the Trump administration deal promising steep price cuts for Medicare, Medicaid, and cash payers, requiring substantial volume growth to offset revenue impact. Source: Morningstar
- Capital expenditure execution risk with $50 billion commitment: Lilly has committed at least $27 billion for new U.S. manufacturing plants announced in February 2025, adding to $23 billion invested since 2020, with an additional $3.5 billion Pennsylvania facility, creating substantial execution risk and capital allocation pressure that could strain financial flexibility. Source: CNBC
- Emerging product liability concerns related to vision loss: Product liability concerns have emerged as an identified risk factor that could impact market perception and create legal exposure, potentially affecting adoption rates and requiring additional safety monitoring investments. Source: Forbes
- Increasing GLP-1 competitive intensity and price competition: Potential GLP-1 price competition represents a growing risk as multiple competitors develop oral and injectable alternatives, with the market's rapid growth attracting significant investment from pharmaceutical companies seeking to capture share in the obesity treatment space. Source: Forbes